Sponsored Links

Supernus Announces Positive Results From Phase IIa Clinical Trial For SPN 810 In Children With ADHD And Serious Conduct Problems PDF Print E-mail
Medical News - ADHD
Supernus Pharmaceuticals Inc., announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus baseline in conduct problems across all doses...

Read more: ADHD News From Medical News Today